Almanac 2013: stable coronary artery disease

Open access

[1] Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012;366:54-63.

[2] Briffa T, Nedkoff L, Peeters A, et al. Discordant age and sex-specific trends in the incidence of a first coronary heart disease event in Western Australia from 1996 to2007. Heart 2011;97:400-4.

[3] Vaartjes I, O’Flaherty M, Grobbee DE, et al. Coronary heart disease mortality trends in the Netherlands 1972-2007. Heart 2011;97:569-73.

[4] Schmidt M, Jacobsen JB, Lash TL, et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 2012;344:e356.

[5] Smolina K, Wright FL, Rayner M, et al. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ 2012;344:d8059.

[6] Nedkoff L, Briffa TG, Knuiman M, et al. Temporal trends in the incidence and recurrence of hospitalised atherothrombotic disease in an Australian population, 2000-07: data linkage study. Heart 2012;98:1449-56.

[7] Pearson-Stuttard J, Bajekal M, Scholes S, et al. Recent UK trends in the unequal burden of coronary heart disease.Heart 2012;98:1573-82.

[8] Kharazmi E, Dossus L, Rohrmann S, et al. Pregnancy loss and risk of cardiovascular disease: a prospective population-based cohort study (EPIC-Heidelberg). Heart 2011;97:49-54.

[9] Safford MM, Brown TM, Muntner PM, et al. Association of race and sex with risk of incident acute coronary heart disease events. JAMA 2012;308:1768-74.

[10] Williams ED, Stamatakis E, Chandola T, et al. Physical activity behaviour and coronary heart disease mortality among South Asian people in the UK: an observational longitudinal study. Heart 2011;97:655-9.

[11] Zaman MJ, Bhopal RS. New answers to three questions on the epidemic of coronary mortality in south Asians: incidence or case fatality? Biology or environment? Will the next generation be affected? Heart 2013;99:154-8.

[12] Fihn SD, Gardin JM, Abrams J, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. ACCF/AHA/ACP/AATS/PCNA/ SCAI/STS Guideline for the diagnosis andmanagement of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.J Am Coll Cardiol 2012;60:e44-164.

[13] Cooper A, Timmis A, Skinner J. Guideline Development Group. Assessment of recent onset chest pain or discomfort of suspected cardiac origin: summary of NICE guidance.BMJ 2010;340:c1118.

[14] Henderson RA, O’Flynn N; Guideline Development Group. Management of stable angina: summary of NICE guidance. Heart 2012;98:500-7.

[15] Taggart DP, Boyle R, de Belder MA, et al. The 2010ESC/EACTS guidelines on myocardial revascularization.Heart 2011;97:445-6.

[16] Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-72.

[17] D’Ascenzo F, Presutti DG, Picardi E, et al. Prevalence and non-invasive predictors of left main or three-vessel coronary disease: evidence from a collaborative international meta-analysis including 22 740 patients. Heart 2012;98:914-9.

[18] Cacoub PP, Zeymer U, Limbourg T, et al. Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe. Heart 2011;97:660-7.

[19] Kotseva K, Jennings CS, Turner EL, et al. A survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. Heart 2012;98:865-71.

[20] Stewart K, Walters M, Dawson J. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90). Heart 2011;97:585-6.

[21] Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354e62.

[22] Bouman HJ, Harmsze AM, van Werkum JW, et al.Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-44.

[23] Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.J Am Coll Cardiol 2010;56:134e43.

[24] Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012;98:100-8.

[25] Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.JAMA 2011;306:2704-14.

[26] Focks JJ, Brouwer MA, van Oijen MG, et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome - a systematic review. Heart 2013;99:520-7.

[27] Park KW, Kang J, Park JJ, et al. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. Heart 2012;98:1366-72.

[28] Li AY, Ng FH, Chan FK, et al. Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: a randomised, controlled trial.Heart 2013;99:468-73.

[29] Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease.N Engl J Med 2011;365:2078-87.

[30] The AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy.N Engl J Med 2011;365:2255-67.

[31] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.

[32] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome.N Engl J Med 2012;367:2089-99.

[33] Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.

[34] Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109.

[35] Neefjes LA, Ten Kate GJ, Rossi A, et al. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia.Heart 2011;97:1151-7.

[36] Cuchel M, Meagher EA, du Toit, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40-6.

[37] Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.

[38] Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.

[39] Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011;97:1175-81.

[40] Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013;381:1293-301.

[41] Gray J, Jaiyeola A, Whiting M, et al. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre.Heart 2008;94:754-8.

[42] Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease.N Engl J Med 2007;356:1503-16.

[43] Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease.N Engl J Med 2008;359:677-87.

[44] Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:312-19.

[45] Borden WB, Redberg RF, Mushlin AI, et al. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 2011;305:1882-9.

[46] De Bruyne B, Pijls NH, Kalesan B, et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991-1001.

[47] Boden WE. COURAGE 5 years on: the message grows stronger. Heart 2012;98:1757-60.

[48] Hillis LD, Smith PK, Anderson JL, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons.J Am Coll Cardiol 2011;58:e123-210.

[49] Farooq V, Brugaletta S, Serruys PW. Contemporary and evolving risk scoring algorithms for percutaneous coronary intervention. Heart 2011;97:1902-13.

[50] Hlatky MA, Boothroyd DB, Baker L, et al. Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention: a cohort study. Ann Intern Med 2013;158:727-34.

[51] Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al.Comparative effectiveness of revascularization strategies.N Engl J Med 2012;366:1467-76.

[52] Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013;381:629-38.

[53] Farkouh ME, Domanski M, Sleeper LA, et al. FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367:2375-84.

[54] Chieffo A, Meliga E, Latib A, et al. Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv 2012;5:718-27.

[55] Chang K, Koh YS, Jeong SH, et al. Long-term outcomes of percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main coronary bifurcation disease in the drug-eluting stent era. Heart 2012; 98:799-805.

[56] Lopes RD, Hafley GE, Allen KB, et al. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med 2009;361:235-44.

[57] Barnard JB, Keenan DJ. National Institute for Health and Clinical Excellence. Endoscopic saphenous vein harvesting for coronary artery bypass grafts: NICE guidance.Heart 2011;97:327-9.

[58] Williams JB, Peterson ED, Brennan JM, et al. Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. JAMA 2012;308:475-84.

[59] Grant SW, Grayson AD, Zacharias J, et al. What is the impact of endoscopic vein harvesting on clinical outcomes following coronary artery bypass graft surgery? Heart 2012;98:60-4.

[60] Pepper JR. NICE guidance for off-pump CABG: keep the pump primed. Heart 2011;97:1728-30.

[61] Falk V, Taggart DP. NICE guidance for off-pump CABG: turn off the pump. Heart 2011;97:1731-3.

[62] Møller CH, Perko MJ, Lund JT, et al. Three-year follow-up in a subset of high-risk patients randomly assigned to off-pump versus on-pump coronary artery bypass surgery: the Best Bypass Surgery trial. Heart 2011;97:907-13.

[63] Hattler B, Messenger JC, Shroyer AL, et al. Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group.Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial. Circulation 2012;125:2827-35.

[64] Anastasiadis K, Argiriadou H, Kosmidis MH, et al. Neurocognitive outcome after coronary artery bypass surgery using minimal versus conventional extracorporeal circulation: a randomised controlled pilot study. Heart 2011;97:1082-8.

[65] Er F, Nia AM, Dopp H, et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial).Circulation 2012;126:296-303.

[66] Xie JJ, Liao XL, Chen WG, et al. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing heart valve surgery: randomised controlled trial.Heart 2012;98:384-8.

[67] Bøtker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375:727-34.

[68] Rahman IA, Mascaro JG, Steeds RP, et al. Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to disappointment? Circulation 2010;122(11 Suppl):S53-9.

[69] D’Ascenzo F, Cavallero E, Moretti C, et al. Remote ischaemic preconditioning in coronary artery bypass surgery: a meta-analysis. Heart 2012;98:1267-71.

[70] Battipaglia I, Scalone G, Milo M, et al. Upper arm intermittent ischaemia reduces exercise-related increase of platelet reactivity in patients with obstructive coronary artery disease. Heart 2011;97:1298-303.

[71] Pedersen CM, Schmidt MR, Barnes G, et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemia-reperfusion injury in vivo in man. Heart 2011;97:1857-61.

[72] Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012;98:683-90.

[73] Moons KG, Kengne AP, Grobbee DE, et al. Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012;98:691-8.

[74] Hemingway H, Philipson P, Chen R, et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 2010;7: e1000286.

[75] Sutaria S, Philipson P, Fitzpatrick NK, et al. Translational phases of evidence in a prognostic biomarker: a systematic review and meta-analysis of natriuretic peptides and the prognosis of stable coronary disease. Heart 2012;98:615-22.

[76] Beatty AL, Ku IA, Christenson RH, et al. High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the heart and soul study. JAMA Intern Med 2013;173:763-9.

[77] Omland T, Pfeffer MA, Solomon SD, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.J Am Coll Cardiol 2013;61:1240-9.

[78] Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart 2011;97:823-31.

[79] Brouwers FP, de Boer RA, van der Harst P, et al. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart 2012;98:1348-53.

[80] Held C, Hjemdahl P, Eriksson SV, et al. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J 2001;22:62-72.

[81] Xie W, Liang L, Zhao L, et al. Combination of carotid intima-media thickness and plaque for better predicting risk of ischaemic cardiovascular events. Heart 2011;97:1326-31.

[82] Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012;308:796-803.

[83] Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012;379:2053-62.

[84] Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.

[85] Li K, Kaaks R, Linseisen J, et al. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012;98:920-5.

[86] Williams DM, Fraser A, Lawlor DA. Associations of vitamin D, parathyroid hormone and calcium with cardiovascular risk factors in US adolescents. Heart 2011;97:315-20.

[87] Grandi NC, Brenner H, Hahmann H, et al. Calcium, phosphate and the risk of cardiovascular events and all-cause mortality in a population with stable coronary heart disease.Heart 2012;98:926-33.

[88] Grandi NC, Breitling LP, Hahmann H, et al. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart 2011;97:1215-21.

Seminars in Cardiovascular Medicine

The Journal of Lithuanian Heart Association

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 93 93 10
PDF Downloads 34 34 5